Onco-haematology is a sub-specialty of haematology that focuses specifically on cancers of the blood cells and haematopoietic organs (bone marrow, lymph nodes, spleen).
We offer a full range of onco-haematology services to diagnose, treat and monitor the following pathologies:
Leukaemias are cancers that can develop from different types of precursor cells and are classified according to their rate of progression (acute or chronic) and the type of cell affected (myeloid or lymphoid). Once an accurate diagnosis has been made, treatments include chemotherapy, targeted therapies and, in some cases, stem cell transplants to maximise the chances of remission, depending on the type of leukaemia.
Lymphomas are cancers of the lymphocytes, a type of white blood cell in the immune system. They develop mainly in the lymph nodes, but can also affect other lymphoid organs such as the spleen or tonsils. There are two main types of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma.
Lymphoma treatment requires a specific approach depending on the type of lymphoma, and includes options such as chemotherapy, radiotherapy, immunotherapy and targeted therapies. Active surveillance may be sufficient for indolent lymphomas.
Multiple myeloma is a cancer of the plasma cells, a type of white blood cell that produces antibodies.
For myeloma patients, we provide comprehensive care with advanced treatment options added to standard protocols, such as monoclonal antibody treatments, to improve quality of life and limit symptoms.
We use the latest technological advances to treat haematological cancers, including a combination of innovative treatments and cutting-edge technologies to offer more targeted and effective management: